Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations

被引:51
作者
Reuman, Elizabeth C. [1 ]
Rhee, Soo-Yon [1 ]
Holmes, Susan P. [2 ]
Shafer, Robert W. [1 ]
机构
[1] Stanford Univ, Dept Med, Div Infect Dis, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Stat, Stanford, CA 94305 USA
基金
美国国家卫生研究院;
关键词
Multidrug resistance; etravirine; antiviral therapy; ETRAVIRINE TMC-125; INFECTED PATIENTS; WILD-TYPE; EFAVIRENZ; NEVIRAPINE; PREVALENCE; DATABASE; FAILURE;
D O I
10.1093/jac/dkq140
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: We characterized pairwise and higher order patterns of non-nucleoside reverse transcriptase inhibitor (NNRTI)-selected mutations because multiple mutations are usually required for clinically significant resistance to second-generation NNRTIs. Patients and methods: We analysed viruses from 13039 individuals with sequences containing at least one of 52 published NNRTI-selected mutations, including 1133 viruses from individuals who received efavirenz but no other NNRTI and 1510 viruses from individuals who received nevirapine but no other NNRTI. Of the 17 reported etravirine resistance-associated mutations (RAMs), Y181C/I/V, L100I, K101P and M230L were considered major based on published in vitro susceptibility data. Results: Efavirenz preferentially selected for 16 mutations, including L100I (14% versus 0.1%, P<0.001), K101P (3.3% versus 0.4%, P<0.001) and M230L (2.8% versus 1.3%, P=0.004), whereas nevirapine preferentially selected for 12 mutations, including Y181C/I/V (48% versus 6.9%, P<0.001). Twenty-nine pairs of NNRTI-selected mutations covaried significantly, including Y181C with seven other mutations (A98G, K101E/H, V108I, G190A/S and H221Y), L100I with K103N, and K101P with K103S. Two pairs (Y181C+V179F and Y181C+G190S) were predicted to confer >10-fold decreased etravirine susceptibility. Seventeen percent of sequences had three or more NNRTI-selected mutations, mostly in clusters of covarying mutations. Many clusters had Y181C plus a non-major etravirine RAM; few had more than one major etravirine RAM. Conclusions: Although major etravirine RAMs rarely occur in combination, 2 of 29 pairs of covarying mutations were associated with >10-fold decreased etravirine susceptibility. Viruses with three or more NNRTI-selected mutations often contained Y181C in combination with one or more minor etravirine RAMs; however, phenotypic and clinical correlates for most of these higher order combinations have not been published.
引用
收藏
页码:1477 / 1485
页数:9
相关论文
共 29 条
[1]   Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA [J].
不详 .
AIDS, 2008, 22 (03) :367-376
[2]   Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure [J].
Antinori, A ;
Zaccarelli, M ;
Cingolani, A ;
Forbici, F ;
Rizzo, MG ;
Trotta, MP ;
Di Giambenedetto, S ;
Narciso, P ;
Ammassari, A ;
Girardi, E ;
De Luca, A ;
Perno, CF .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2002, 18 (12) :835-838
[3]   TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1 [J].
Azijn, Hilde ;
Tirry, Ilse ;
Vingerhoets, Johan ;
de Bethune, Marie-Pierre ;
Kraus, Guenter ;
Boven, Katia ;
Jochmans, Dirk ;
Van Craenenbroeck, Elke ;
Picchio, Gaston ;
Rimsky, Laurence T. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (02) :718-727
[4]   Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy [J].
Bacheler, L ;
Jeffrey, S ;
Hanna, G ;
D'Aquila, R ;
Wallace, L ;
Logue, K ;
Cordova, B ;
Hertogs, K ;
Larder, B ;
Buckery, R ;
Baker, D ;
Gallagher, K ;
Scarnati, H ;
Tritch, R ;
Rizzo, C .
JOURNAL OF VIROLOGY, 2001, 75 (11) :4999-5008
[5]   Evidence for positive epistasis in HIV-1 [J].
Bonhoeffer, S ;
Chappey, C ;
Parkin, NT ;
Whitcomb, JM ;
Petropoulos, CJ .
SCIENCE, 2004, 306 (5701) :1547-1550
[6]   Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors [J].
Ceccherini-Silberstein, Francesca ;
Svicher, Valentina ;
Sing, Tobias ;
Artese, Anna ;
Santoro, Maria Mercedes ;
Forbici, Federica ;
Bertoli, Ada ;
Alcaro, Stefano ;
Palamara, Guido ;
Monforte, Antonella d'Arminio ;
Balzarini, Jan ;
Antinori, Andrea ;
Lengauer, Thomas ;
Perno, Carlo Federico .
JOURNAL OF VIROLOGY, 2007, 81 (20) :11507-11519
[7]  
COAKLEY E, 2009, 16 C RETR OPP INF MO
[8]   Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants [J].
Das, K ;
Clark, AD ;
Lewi, PJ ;
Heeres, J ;
de Jonge, MR ;
Koymans, LMH ;
Vinkers, HM ;
Daeyaert, F ;
Ludovici, DW ;
Kukla, MJ ;
De Corte, B ;
Kavash, RW ;
Ho, CY ;
Ye, H ;
Lichtenstein, MA ;
Andries, K ;
Pauwels, R ;
de Béthune, MP ;
Boyer, PL ;
Clark, P ;
Hughes, SH ;
Janssen, PAJ ;
Arnold, E .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (10) :2550-2560
[9]   Bayesian network analyses of resistance pathways against efavirenz and nevirapine [J].
Deforche, Koen ;
Camacho, Ricardo J. ;
Grossman, Zehave ;
Soares, Marcelo A. ;
Van Laethem, Kristel ;
Katzenstein, David A. ;
Harrigan, P. Richard ;
Kantor, Rami ;
Shafer, Robert ;
Vandamme, Anne-Mieke .
AIDS, 2008, 22 (16) :2107-2115
[10]   Combination of V106I and V179D Polymorphic Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Resistance to Efavirenz and Nevirapine but Not Etravirine [J].
Gatanaga, Hiroyuki ;
Ode, Hirotaka ;
Hachiya, Atsuko ;
Hayashida, Tsunefusa ;
Sato, Hironori ;
Oka, Shinichi .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (04) :1596-1602